

Highlights of This Issue 3359

SPECIAL FEATURES

CCR Translations

- 3361** MET as a Target in Papillary Renal Cell Carcinoma
 André P. Fay, Sabina Signoretti, and Toni K. Choueiri
See related article, p. 3411

CCR Perspectives in Drug Approval

- 3364** U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
 Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

Statistics in Clinical Cancer Research

- 3371** Blocking and Randomization to Improve Molecular Biomarker Discovery
 Li-Xuan Qin, Qin Zhou, Faina Bogomolny, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

Molecular Pathways

- 3379** Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
 Mark A. Dickson
- 3384** Molecular Pathways: Niches in Metastatic Dormancy
 Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

Review

- 3390** Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
 Wing Leung

HUMAN CANCER BIOLOGY

- 3401** Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
 Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yarden Samuels, Steven A. Rosenberg, and Paul F. Robbins
- 3411** MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
 Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahira Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
See related article, p. 3361
- 3422** Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
 Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Offringa, Jens Werner, and Eduard Ryschich
- 3434** Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
 Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

CANCER THERAPY: PRECLINICAL

- 3446** Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
 Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjoern Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas

Table of Contents

- 3458** Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Alba Matas-Céspedes, Vanina Rodriguez, Susana G. Kalko, Anna Vidal-Crespo, Laia Rosich, Teresa Casserras, Patricia Balsas, Neus Villamor, Eva Giné, Elías Campo, Gaël Roué, Armando López-Guillermo, Dolores Colomer, and Patricia Pérez-Galán
- 3472** Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang
- 3485** Synergistic Anticancer Effects of Pam₃CSK₄ and Ara-C on B-Cell Lymphoma Cells
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser
- 3496**  Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Gianmaria Liccardi, John A. Hartley, and Daniel Hochhauser
- 3507** Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, and Dennis J. Slamon
- 3521** Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandria T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

IMAGING, DIAGNOSIS, PROGNOSIS

- 3531** *In Vivo* Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Yasaman Ardeshirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandjbakhche

- 3540** Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker, Wolfgang Bogner, Pascal Baltzer, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsy, Zsuzsanna Bago-Horvath, Rupert Bartsch, Michael Weber, Siegfried Trattning, and Thomas H. Helbich
- 3550** Treatment Response Evaluation Using ¹⁸F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
Johannes Schwarzenberg, Johannes Czernin, Timothy F. Cloughesy, Benjamin M. Ellingson, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen
- 3560** Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persigehl, David P. Mozley, and Lawrence H. Schwartz
- 3569**  TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Børresen-Dale, Carlos Caldas, and Anita Langerød

CANCER THERAPY: CLINICAL


- 3581**  A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton
- 3589** Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herndlhofer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sperr, Matthias Mayerhofer, Thomas Rüllicke, and Peter Valent

Table of Contents

- 3603** Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 3613** Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with *EGFR* Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>


For more information please visit www.aacrjournals.org

LETTERS TO THE EDITOR

- 3623** SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti
- 3625** SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O'Brien and colleagues on page 3507 of this issue.



Clinical Cancer Research

20 (13)

Clin Cancer Res 2014;20:3359-3626.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/13>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/13>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.